ArticleSleep & breathing = Schlaf & Atmung2025
Association of cerebrospinal fluid FGF21 with sleep quality in Chinese adults.
Article in Sleep & breathing = Schlaf & Atmung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveThis study aimed to examine whether FGF21 levels in cerebrospinal fluid (CSF) and plasma are associated with sleep quality, as measured by the Pittsburgh Sleep Quality Index (PSQI) scores, and to assess the correlation between FGF21 levels and sleep disorder severity.
methodsWe recruited 90 Chinese adult males undergoing anterior cruciate ligament reconstruction surgery, gathering sociodemographic and clinical characteristics. Sleep quality was assessed using the PSQI, and CSF samples were obtained for FGF21 analysis.
resultsSpearman's correlation analysis showed that CSF FGF21 levels were positively correlated with PSQI global scores (r = 0.51, p < 0.001), as well as with specific components, including sleep quality (r = 0.32, p < 0.01), sleep latency (r = 0.46, p < 0.001), sleep disturbances (r = 0.53, p < 0.001), and daytime dysfunction (r = 0.55, p < 0.001). CSF FGF21 levels also positively correlated with APOA1 levels. However, plasma FGF21 levels showed no correlation with these sleep parameters. Elevated CSF FGF21 levels were associated with higher PSQI scores and increased prevalence of prolonged sleep latency, sleep disturbances, and daytime dysfunction. The association between CSF FGF21 levels and sleep disorders remained significant after adjusting for age, BMI, education, living situation, marital status, and biochemical markers.
conclusionsThis study identifies a novel positive association between CSF FGF21 levels, rather than plasma FGF21, and sleep quality, as assessed by PSQI scores, particularly in subcategories including low sleep quality, prolonged sleep latency, severe sleep disturbances, and marked daytime dysfunction in healthy adults.
Indexed as
Identifiers
40906257What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.